Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMTX-100 CF in Atopic Dermatitis
NCT04313400Phase 2Completed
- Sponsor
- Amytrx Therapeutics
- Start
- Mar 2020
- Primary completion
- Dec 2023
- Modality
- Modified Peptides, Peptide-Protein Conjugates, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of amtx-100 in atopic dermatitis (AD), sponsored by Amytrx Therapeutics. Started Mar 2020; status: completed.
02
Drugs
amtx-100
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04313400.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313400.